Product News

Share this article:
Merck's overseas affiliate MSD said that Isentress (raltegravir) has been granted a license from the European Union Commission for use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The FDA granted approval for Isentress in October.

Pfizer said it received an FDA approvable letter for dalbavancin HCl, its once-weekly two-dose antibiotic under review for treating adults with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.